Eloralintide LY3841136 Phase 1 & Development

How did eloralintide get from the lab to clinical trials? Eloralintide (development code LY3841136) is an Eli Lilly amylin receptor agonist. Before the 48-week phase 2 trial, researchers published cell and animal studies plus two phase 1 studies on safety, how long the drug lasts in the body, and early weight changes.

This original FirstLabs editorial review was updated November 3, 2026. It is educational information, not medical advice, a dosing guide or a recommendation for personal use. FirstLabs catalogue materials are for laboratory research only, not human or veterinary use.

Preclinical studies in rats and monkeys

Lilly researchers tested eloralintide in cell lines expressing amylin and calcitonin receptors, then in rats and monkeys. In diet-induced obese rats, it reduced food intake and lowered body weight in a dose-dependent way, mainly through fat-mass loss. Pharmacokinetic data in both species supported a long-acting profile.

Animal findings help choose compounds for human testing. They do not predict human benefit or safety on their own.

Phase 1 single-dose study in healthy adults

A randomized, placebo-controlled single-ascending-dose study enrolled 48 healthy participants with a mean BMI of 27.5. Nine participants in the eloralintide groups reported 16 adverse events; 15 were mild. Two participants reported four gastrointestinal events, including one moderate vomiting event.

Four weeks after a single administration, the two highest-exposure groups showed mean weight changes of −2.5% and −4.4%, compared with +0.6% on placebo. The pharmacokinetic profile supported once-weekly administration in later trials.

Phase 1 multiple-dose study: 100 participants over 12 weeks

Bhattachar and colleagues ran a 12-week multiple-ascending-dose study in 100 adults with obesity or overweight at three U.S. centres, with a mean BMI of 32.6. Exposure increased in proportion to the amount given.

The most common adverse events with eloralintide were decreased appetite (19%), headache (12%), fatigue (11%) and COVID-19 (11%). Diarrhoea (10%), nausea (8%) and vomiting (4%) were less frequent. Mean body-weight reduction at week 12 ranged from 2.6% to 11.3% across groups.

Phase 1 studies are small and short. Their main purpose is safety and pharmacokinetics, not proof of long-term effectiveness.

Where eloralintide stands now

After phase 1, the 48-week phase 2 trial tested several dose groups. Phase 3 results are needed before any regulator can evaluate it. Eloralintide is not approved by Health Canada, the FDA or any other regulator. All studies described here were funded by Eli Lilly, and most authors are company employees.

Eloralintide development: frequently asked questions

What is LY3841136?

It is Eli Lilly's development code for eloralintide.

Who makes eloralintide?

Eli Lilly is developing it as an investigational obesity treatment. Research vials sold by suppliers are not Lilly products.

Is eloralintide in phase 3?

Check the official trial registry for current status; this article reflects published phase 1 and phase 2 results.

Laboratory documentation is a separate question

Evidence about eloralintide in a clinical study does not establish that a FirstLabs vial is equivalent to the studied formulation. A certificate of analysis describes the submitted sample, not medical suitability or regulatory authorization. HPLC purity does not by itself establish quantity, sterility, endotoxin control or a match to current stock.

For laboratory records, verify exact identity and labelled size, analytical methods, measured quantity, sample identifiers and any available lot-to-stock documentation. A laboratory task ID is not automatically a manufacturing lot. Keep missing reports and adverse results visible rather than borrowing evidence from another size.

Related reading: Eloralintide phase 2 results, receptor selectivity and the Eloralintide Canada guide. The Eloralintide 10mg catalogue entry is for laboratory research only. The cover is an illustrative laboratory scene.

Read our COA verification checklist, published laboratory reports and Canadian regulation overview for these distinctions.

Primary sources and editorial scope

FirstLabs is a research-material supplier with a commercial interest in the compounds discussed, not a licensed pharmacy or an independent medical authority. Results belong to their original study populations, formulations and endpoints. No personal outcome, treatment protocol or authorization of catalogue products is implied.

Eloralintide (LY3841136) Development: Preclinical and Phase 1 Studies